| Identification | Back Directory | [Name]
9-OXO-11ALPHA,15S-DIHYDROXY-PROSTA-5Z,13E,17Z-TRIEN-1-OIC ACID | [CAS]
802-31-3 | [Synonyms]
PGE3
PROSTAGLANDIN E3
Prostaglandin E3 Exclusive
9-OXO-11ALPHA,15S-DIHYDROXY-PROSTA-5Z,13E,17Z-TRIEN-1-OIC ACID
(5Z,13E,15S,17Z)-11α,15-Dihydroxy-9-oxoprosta-5,13,17-trien-1-oic acid
(5Z,11a,13E,15S,17Z) 11,15-dihydroxy-9-oxo-prosta-5,13,17-trien-1-oic acid
Prosta-5,13,17-trien-1-oic acid, 11,15-dihydroxy-9-oxo-, (5Z,11α,13E,15S,17Z)- | [Molecular Formula]
C20H30O5 | [MDL Number]
MFCD00065758 | [MOL File]
802-31-3.mol | [Molecular Weight]
350.45 |
| Chemical Properties | Back Directory | [Melting point ]
84.5-85.5 °C | [Boiling point ]
541.0±50.0 °C(Predicted) | [density ]
1.166±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMF: >100 mg/ml (from PGE2); DMSO: >100 mg/ml (from PGE2); Ethanol: >100 mg/ml (from PGE2); PBS pH 7.2: >5 mg/ml (from PGE2) | [form ]
Liquid | [pka]
4.75±0.10(Predicted) | [color ]
Colorless to light yellow |
| Hazard Information | Back Directory | [Uses]
Prostaglandin E3 (PGE3) is formed via the cyclooxygenase (COX) metabolism of eicosapentaenoic acid. In human ocular tissue, it comprises 2.4% of the COX products formed. When applied to the eyes of a rabbit, a 1 μg dose of PGE3 decreases intraocular pressure from 21 mmHg to about 17 mmHg. | [Definition]
ChEBI: Prostaglandin E3 is a prostaglandins E. It has a role as a human metabolite. It is a conjugate acid of a prostaglandin E3(1-). | [in vivo]
Prostaglandin E3 (1 μmol/L; i.p.) modulates macrophage polarization towards an anti-inflammatory function in LPS (HY-D1056) (5 mg/kg)-induces acute inflammation model[1].
Prostaglandin E3 (1 μmol/L; every 3 days for 4 weeks) shows anti-tumor activity by regulates macrophage polarization[1]. | Animal Model: | 5 weeks, Nude mice (BABL/c) (PC3 xenograft model)[1] | | Dosage: | 1 μmol/L for 50 μL | | Administration: | Injected next to the tumour, every 3 days for 4 weeks | | Result: | Decreased the weights of transplanted tumours, inhibits the expression of CD68 and CD206. |
| Animal Model: | 6-8-week-old C57BL6/J mice[1] | | Dosage: | LPS+ PGE3 (5 mg/kg + 1 μmol/L) | | Administration: | I.p.; once | | Result: | Significantly reduced MPMs with an M1-like phenotype and increased M2-like MPMs, inhibited inflammatory cytokine secretion in both the serum and MPM cell lysates. |
| [storage]
Store at -20°C |
|
| Company Name: |
amyjet
|
| Tel: |
4006800868;027-59626688 18371453821;18771149750 |
| Website: |
http://www.amyjet.com/ |
|